Trial Profile
A Pilot Study of the fMRI Response to Leptin and Pramlintide
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs Metreleptin (Primary) ; Pramlintide (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- 14 Dec 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2024.
- 14 Dec 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2024.
- 27 Jul 2021 Planned End Date changed from 1 Jul 2020 to 1 Jul 2022.